Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice.
NZB/NZW mice were treated with various immunosuppressive drugs used in human SLE. Cyclophosphamide (5 mg/kg 6 days out of 7), alone or with prednisolone, was better than azathioprine, prednisolone, or azathioprine-plus-prednisolone, in prolonging survival and/or reducing proteinuria, Coomb's antibodies, antinuclear antibodies, and glomerular deposits of gamma-globulin. Intermittent bolus therapy with cyclophosphamide (59 mg/kg/10 days) was as effective as daily therapy. However, 61% of the mice receiving any cyclophosphamide regimen developed malignant tumors compared to none in the other groups.
D000818:Animals; D001323:Autoantibodies; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D002277:Carcinoma / Q000139:chemically induced; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004359:Drug Therapy, Combination; D005260:Female; D007154:Immune System Diseases / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007942:Leukemia, Experimental / Q000139:chemically induced; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008297:Male; D051379:Mice; D008814:Mice, Inbred NZB; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D009393:Nephritis / Q000188:drug therapy; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D012513:Sarcoma, Experimental / Q000139:chemically induced
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone; D001379:Azathioprine